332 related articles for article (PubMed ID: 37980602)
1. Mechanisms of Ovarian Cancer-Associated Cachexia.
Callaway CS; Mouchantat LM; Bitler BG; Bonetto A
Endocrinology; 2023 Nov; 165(1):. PubMed ID: 37980602
[TBL] [Abstract][Full Text] [Related]
2. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia.
Pin F; Barreto R; Kitase Y; Mitra S; Erne CE; Novinger LJ; Zimmers TA; Couch ME; Bonewald LF; Bonetto A
J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):685-700. PubMed ID: 30009406
[TBL] [Abstract][Full Text] [Related]
3. Development of ovarian tumour causes significant loss of muscle and adipose tissue: a novel mouse model for cancer cachexia study.
Luan Y; Zhang Y; Yu SY; You M; Xu PC; Chung S; Kurita T; Zhu J; Kim SY
J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1289-1301. PubMed ID: 35044098
[TBL] [Abstract][Full Text] [Related]
4. Deliberation on debilitating condition of cancer cachexia: Skeletal muscle wasting.
Dave S; Patel BM
Fundam Clin Pharmacol; 2023 Dec; 37(6):1079-1091. PubMed ID: 37474262
[TBL] [Abstract][Full Text] [Related]
5. Withaferin A ameliorates ovarian cancer-induced cachexia and proinflammatory signaling.
Straughn AR; Kakar SS
J Ovarian Res; 2019 Nov; 12(1):115. PubMed ID: 31767036
[TBL] [Abstract][Full Text] [Related]
6. Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know?
Dolly A; Dumas JF; Servais S
J Cachexia Sarcopenia Muscle; 2020 Dec; 11(6):1413-1428. PubMed ID: 33053604
[TBL] [Abstract][Full Text] [Related]
7. Cancer-Mediated Muscle Cachexia: Etiology and Clinical Management.
Siff T; Parajuli P; Razzaque MS; Atfi A
Trends Endocrinol Metab; 2021 Jun; 32(6):382-402. PubMed ID: 33888422
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of muscle wasting in cancer cachexia: targeted anabolic and anticatabolic therapies.
Burckart K; Beca S; Urban RJ; Sheffield-Moore M
Curr Opin Clin Nutr Metab Care; 2010 Jul; 13(4):410-6. PubMed ID: 20473155
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer ascites induces skeletal muscle wasting in vitro and reflects sarcopenia in patients.
Ubachs J; van de Worp WRPH; Vaes RDW; Pasmans K; Langen RC; Meex RCR; van Bijnen AAJHM; Lambrechts S; Van Gorp T; Kruitwagen RFPM; Olde Damink SWM; Rensen SS
J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):311-324. PubMed ID: 34951138
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans?
Mueller TC; Bachmann J; Prokopchuk O; Friess H; Martignoni ME
BMC Cancer; 2016 Feb; 16():75. PubMed ID: 26856534
[TBL] [Abstract][Full Text] [Related]
11. RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non-Metastatic Ovarian Cancer in Mice.
Pin F; Jones AJ; Huot JR; Narasimhan A; Zimmers TA; Bonewald LF; Bonetto A
J Bone Miner Res; 2022 Mar; 37(3):381-396. PubMed ID: 34904285
[TBL] [Abstract][Full Text] [Related]
12. Lithium Chloride Protects against Sepsis-Induced Skeletal Muscle Atrophy and Cancer Cachexia.
Lee JH; Kim SW; Kim JH; Kim HJ; Um J; Jung DW; Williams DR
Cells; 2021 Apr; 10(5):. PubMed ID: 33925786
[TBL] [Abstract][Full Text] [Related]
13. Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions.
Siddiqui JA; Pothuraju R; Jain M; Batra SK; Nasser MW
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188359. PubMed ID: 32222610
[TBL] [Abstract][Full Text] [Related]
14. Alantolactone ameliorates cancer cachexia-associated muscle atrophy mainly by inhibiting the STAT3 signaling pathway.
Shen Q; Kuang JX; Miao CX; Zhang WL; Li YW; Zhang XW; Liu X
Phytomedicine; 2022 Jan; 95():153858. PubMed ID: 34861585
[TBL] [Abstract][Full Text] [Related]
15. Cancer cachexia: molecular mechanisms and treatment strategies.
Setiawan T; Sari IN; Wijaya YT; Julianto NM; Muhammad JA; Lee H; Chae JH; Kwon HY
J Hematol Oncol; 2023 May; 16(1):54. PubMed ID: 37217930
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia.
Argilés JM; Busquets S; Felipe A; López-Soriano FJ
Int J Biochem Cell Biol; 2005 May; 37(5):1084-104. PubMed ID: 15743680
[TBL] [Abstract][Full Text] [Related]
18. Skeletal muscle omics signatures in cancer cachexia: perspectives and opportunities.
Gilmore LA; Parry TL; Thomas GA; Khamoui AV
J Natl Cancer Inst Monogr; 2023 May; 2023(61):30-42. PubMed ID: 37139970
[TBL] [Abstract][Full Text] [Related]
19. MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer.
Judge SM; Deyhle MR; Neyroud D; Nosacka RL; D'Lugos AC; Cameron ME; Vohra RS; Smuder AJ; Roberts BM; Callaway CS; Underwood PW; Chrzanowski SM; Batra A; Murphy ME; Heaven JD; Walter GA; Trevino JG; Judge AR
Cancer Res; 2020 May; 80(9):1861-1874. PubMed ID: 32132110
[TBL] [Abstract][Full Text] [Related]
20. [Physiology of sarcopenia. Similarities and differences with neoplasic cachexia (muscle impairments in cancer and ageing)].
Argilés JM; Busquets S; López-Soriano FJ; Figueras M
Nutr Hosp; 2006 May; 21 Suppl 3():38-45. PubMed ID: 16768029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
